LATEST ALERTS
The panel responsible for recommending which drugs England’s National Health Service (NHS) should prescribe may recommend against the organisation using cannabis-based medical products. The National Institute for Health and Care Excellence (NICE) has issued draft guidelines which say that in many cases, medical cannabis is both too expensive to be cost-effective and not well-researched enough to be recommended.
...Are you already a subscriber? login here
CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
